Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.
Eldad J. Dann(Rambam Health Care Campus), Ora Paltiel(Hebrew University of Jerusalem), Kalman Filanovsky(Kaplan Medical Center), Abraham Korenberg(Assaf Harofeh Medical Center), Marina Izak(World Health Organization Regional Office for South-East Asia), Ofer Shpilberg(Texas Oncology), Osnat Bairey(Tel Aviv University), Luiza Akria(Western Galilee Hospital), Jacob M. Rowe(Technion – Israel Institute of Technology), Neta Goldschmidt(National Institutes of Health), Ron Epelbaum(University of Bern), Dina Ben Yehuda(Hadassah Medical Center), Rachel Bar‐Shalom(Rambam Health Care Campus), Dina Attias(Bnai Zion Medical Center), L. Abdach(Rambam Health Care Campus)
Cited by 4
Related Papers
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k